iTonic Holdings (ITOC) Stock Price, News & Analysis
Company Description
iTonic Holdings Ltd (ITOC) provides healthcare solutions for brachytherapy, a targeted form of radiation therapy used in cancer treatment. The company operates through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., and focuses on treatment planning systems and related products and services used in brachytherapy procedures.
The company's lead product is Beijing Feitian's Treatment Planning System. The system supports planning for brachytherapy, in which radioactive sources are placed inside the patient to kill cancer cells and shrink tumors. iTonic's reported product portfolio also includes medical auxiliary supplies associated with brachytherapy procedures, such as seed implant needles, computer workstations and patient positioning devices.
iTonic Holdings was founded in 1998 and is based in Beijing, China. Its Class A ordinary shares are associated with Nasdaq listing requirements, including the minimum bid price rule disclosed in the company's public communications. The company's public-company profile is therefore defined by both its China-based healthcare-technology operating subsidiary and its status as a listed issuer reporting corporate, governance and capital-structure matters.
Stock Performance
iTonic Holdings (ITOC) stock last closed at $0.2881. At a market capitalization of $4.9M, ITOC is classified as a micro-cap stock with approximately 9.4M shares outstanding.
ITOC Rankings
Latest News
iTonic Holdings has 2 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include AI. View all ITOC news →
SEC Filings
iTonic Holdings has filed 5 recent SEC filings, including 3 Form 6-K, 1 Form 3, 1 Form 20-F/A. The most recent filing was submitted on June 23, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ITOC SEC filings →
Financial Highlights
iTonic Holdings generated $523K in revenue in FY2025, retaining a 62.6% gross margin, operating income reached -$5.2M (-991.7% operating margin), and net income was -$5.1M, reflecting a -974.7% net profit margin. Diluted earnings per share stood at $-0.32. The company generated -$3.2M in operating cash flow. With a current ratio of 8.83, the balance sheet reflects a strong liquidity position.
Upcoming Events
Nasdaq compliance deadline
iTonic Holdings has 1 upcoming scheduled event. The next event, "Nasdaq compliance deadline", is scheduled for October 19, 2026 (in 72 days). Investors can track these dates to stay informed about potential catalysts that may affect the ITOC stock price.
Short Interest History
Short interest in iTonic Holdings (ITOC) currently stands at 133.0 thousand shares, up 17.0% from the previous reporting period, representing 1.4% of the shares outstanding. Since January 2026, short interest has increased by 730.9%.
Days to Cover History
Days to cover for iTonic Holdings (ITOC) currently stands at 1.2 days, up 19% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 4.1 days.
ITOC Company Profile & Sector Positioning
iTonic Holdings (ITOC) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.